ClinicalTrials.gg
CompletedNCT01780051Updated May 15, 2013

A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components

A Phase 1 interventional study of Repaglinide/Metformin combination, Repaglinide, Metformin and Repaglinide/Metformin combination, Repaglinide, Metformin in Diabetes Mellitus, Type 2, sponsored by Dalim BioTech Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-15.

Sponsored by Dalim BioTech Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing repaglinide in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. repaglinide · Diabetes Mellitus, Type 2.

Enrollment
19th of 22
48 · median 101
Started
2013
the only one that year
Phase 1
4 of 22
none open now
Registered
19th of 22
by date
Lead sponsor
1 of 22
Dalim BioTech Co., Ltd.

Among the 22 studies testing repaglinide in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 1, and was the 19th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 22 studies testing repaglinide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About repaglinide

repaglinide: first FDA approval 1997 (PRANDIN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing repaglinide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin hydrochloride 500mg with administration of combination preparation of Repaglinide 2mg and Metformin hydrochloride 500mg in 50 healthy male volunteers.

Read the detailed description

This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin hydrochloride 500mg with administration of combination preparation of Repaglinide 2mg and Metformin hydrochloride 500mg in 50 healthy male volunteers.

  • All the subjects should be admitted one day prior to scheduled study date until 4pm to Chonbuk National University Hospital Clinical Trial Center and they will be served with the same dinner. After dinner, they should keep fast, they are just allowed to drink water until 8am of the study date.

    • According to the randomly designated order, all subjects will be administrated with the study or reference products with 240mL of water at 9am(±2hours) on the first date of the study. The study or the reference products should be swallowed completely, and not to be chewed before swallowing.

      • Study product : Repanorm M 2/500mg (Dalim BioTech Co., Ltd.)
      • Reference products : Metformin HCl 500mg tablet, Repaglinide 2mg tablet

        • Subjects have to fast for 4 hours post administration of the study or reference drugs(water intake is not allowed for 1 hour before and after the administration), and should follow standardized lunch after four hours and dinner 9 hours later from the time of administration

          • Assessment and laboratory test will be performed in accordance with schedule written on the protocol

            • After having 7 days of withdrawal period, the 2nd study period will be done at 9am(±2hours). In contrast of the 1st period, Sequence B which received the study product in 1st period will take the reference drugs for the 2nd period, while the group Sequence A which received reference drugs will take the study drug. The steps of administration of drugs and process of tests are the same with the 1st period
03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes Mellitus, Type 2
  • Pharmacokinetics
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers ages between 20 and 55 years at screening
  2. Subject with (BMI) with the range of 17.5 to 30.5kg/m2 and body weight over 45kg
  3. Signed with the date of signature
  4. With ability to comply with all the scheduled visits, treatment plans; laboratory tests and other processes.

Exclusion criteria

Exclusion Criteria:

  1. Positive of blood, kidney, endocrine, lung, gastro-intestinal, cardiovascular, hepatic, psychiatric, nervous, allergy; or with past and present disease history or symptoms that are .
  2. Any conditions that are likely to affect drug absorption. ex) gastrectomy
  3. Positive on urine drug tests
  4. History of drinking alcohol more than 12 ounces(360mL) of beer, 1.5 ounces(45mL) of liquor; or 21 drinks/week(1drink = 5 ounces(150mL) of wine ) 6months prior to screening
  5. Participation in any other clinical studies within 2months prior to scheduled study drug administration
  6. With Blood pressure of ≥ 160 mmHg(Systolic blood pressure) or ≥ 90 mmHg(Diastolic blood pressure) in sitting position at screening time.
  7. History of any serious substance or alcohol abuse within one year prior to screening
  8. Use of any drugs known to significantly induce or inhibit drug metabolizing enzyme within 30days prior to scheduled study drug administration
  9. Cigarette smoking of over 20 sticks per day.
  10. Use of any prescription drugs or any over the counter drugs within 10days or quintuple half life(whichever is longer) prior to scheduled study drug administration
  11. Donation of whole blood within 2months or any blood products within 1month, prior to scheduled study drug administration
  12. Disability to comply with the guidelines written on the protocol
  13. Severe acute/chronic medical, physical disorder or laboratory test abnormality that are likely to alter the study result and increase the risk by participating in the study and study drug administration
  14. to chief component or of Repaglinide
  15. History of hypersensitivity to Metformin or Biguanide class of drugs
  16. With renal failure or renal inadequacy caused by cardiovascular shock, acute myocardial infarction and sepsis
  17. With Congestive heart failure and undergoing drug treatment.
  18. Patients undergoing radioactive iodine uptake tests, such as intravenous urography, intravenous cholangiography, angiography, computed tomography using radioactive iodine
  19. Patients with type 1 diabetes, acute or chronic metabolic acidosis including diabetic ketoacidosis associated with or without coma
  20. With serious infection or trauma
  21. Malnutrition, starvation; weakness; pituitary insufficiency or adrenal insufficiency
  22. Patients with hepatic failure, pulmonary infarction, serious pulmonary dysfunction, or other conditions associated with hypoxemia, alcohol abuser, or dehydration, diarrhea; vomiting and gastro-intestinal disease
  23. Proven to be unsuitable to participate in this clinical study by an investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Sequence A

    Drug: Repaglinide/Metformin combination, Repaglinide, Metformin

  • Experimental
    Sequence B

    Drug: Repaglinide/Metformin combination, Repaglinide, Metformin

Interventions

  • DrugRepaglinide/Metformin combination, Repaglinide, Metformin

    Drug pages: Repaglinide · Metformin

    Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1. Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2.

  • DrugRepaglinide/Metformin combination, Repaglinide, Metformin

    Drug pages: Repaglinide · Metformin

    Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1. Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2.

06

What researchers measure

Primary outcomes

  1. AUCt and Cmax of repaglinide and metformin

    Time frame: Before study drug administration(0h) and after 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h of study drug administration.

Secondary outcomes

  1. AUC∞, Tmax, t1/2, CL/F and Vd/F of repaglinide and metformin

    Time frame: Before study drug administration(0h) and after 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h of study drug administration.

07

Study locations

1 site
  • Chounbuk National University Hospital
    Jeonju, Jeonbuk, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2013
First posted
Jan 30, 2013
Start
Mar 2013
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
May 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01780051
Lead sponsor
Dalim BioTech Co., Ltd.
Responsible party
Sponsor
First posted
Jan 30, 2013
Start date
Mar 2013
Primary completion
Apr 2013
Completion
Apr 2013
Last update
May 15, 2013

Study contacts

Min-Gul Kim, doctor
principal investigator · Chounbuk National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Repaglinide · Metformin

Start the discussion